Generated by All in One SEO v5.0.0.1, this is an llms.txt file, used by LLMs to index the site.

# Pharma Equity Group

The Future of Repositioning

## Sitemaps

- [XML Sitemap](https://pharmaequitygroup.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [3301e40787322e872854c47cb25a4c0f](https://pharmaequitygroup.com/2023/05/14/3301e40787322e872854c47cb25a4c0f-2/) - 51a32a652f8c48d92a249ac48d2c3c23
- [3301e40787322e872854c47cb25a4c0f](https://pharmaequitygroup.com/2023/05/14/3301e40787322e872854c47cb25a4c0f/) - 51a32a652f8c48d92a249ac48d2c3c23
- [Nærmere oplysninger om transaktionsprocessen mellem Blue Vision A/S og Reponex Pharmaceuticals A/S](https://pharmaequitygroup.com/2022/11/28/naermere-oplysninger-om-transaktionsprocessen-mellem-blue-vision-a-s-og-reponex-pharmaceuticals-a-s/) - Få den nyeste opdatering på transaktionsprocessen mellem Blue Vision A/S og Reponex Pharmaceuticals A/S i Blue Visions meddelelse fra d. 25 november 2022.
- [Reponex Pharmaceuticals A/S fortsætter styrkelsen af selskabets videnskabelige og regulatoriske viden](https://pharmaequitygroup.com/2022/10/12/reponex-pharmaceuticals-a-s-fortsaetter-styrkelsen-af-selskabets-videnskabelige-og-regulatoriske-viden/) - Reponex styrker selskabet med en række førende kapaciteter indenfor kliniske og regulatoriske opgaver. Få samtidig kort information om transaktionen med Blue Vision A/S.
- [Indkaldelse til ekstraordinær generalforsamling i Blue Vision A/S](https://pharmaequitygroup.com/2022/10/05/indkaldelse-til-ekstraordinaer-generalforsamling-i-blue-vision-a-s/) - Den 4 oktober indkaldte Blue Vision A/S til ekstraordinær generalforsamling, som afholdes den 27. oktober 2022.
- [Afsluttet due diligence om køb af Reponex Pharmaceuticals A/S](https://pharmaequitygroup.com/2022/08/31/afsluttet-due-diligence-om-kob-af-reponex-pharmaceuticals-a-s/) - Bestyrelsen for Blue Vision A/S kan meddele at due diligence i forbindelse med akkvisition af selskabskapitalen i Reponex Pharmaceuticals A/S (Reponex) CVR-nr. 30082346 er afsluttet succesfuldt.
- [Meddelelse om afvigelse ved due diligence af Blue Vision A/S](https://pharmaequitygroup.com/2022/08/31/meddelelse-om-afvigelse-ved-due-diligence-af-blue-vision-a-s/) - Bestyrelsen i Reponex har på vegne af aktionærerne gennemført due diligence af Blue Vision A/S.
- [Indkaldelse til ordinær generalforsamling.](https://pharmaequitygroup.com/2022/04/11/indkaldelse-til-ordinaer-generalforsamling/) - Herved indkalder bestyrelsen til ordinær generalforsamling i Reponex Pharmaceuticals A/S til afholdelse torsdag den 21. april 2022, kl. 08.30. Generalforsamlingen afholdes på Rungstedgaard, Rungsted Strandvej 107, 2960 Rungsted Kyst.
- [Referat fra ordinær generalforsamling i Reponex 21/4-22](https://pharmaequitygroup.com/2022/05/23/referat-fra-ordinaer-generalforsamling-i-reponex-21-4-22/) - Den 21. april 2022 blev der afholdt ordinær generalforsamling i Reponex Pharmaceuticals A/S, CVRnr. 30082346.Advokat Martin Allan Christensen blev udpeget til dirigent, jf. vedtægternes pkt. 3.6.
- [Positivt svar fra Reponex Pharmaceuticals A/S på betinget købstilbud](https://pharmaequitygroup.com/2022/05/04/positivt-svar-fra-reponex-pharmaceuticals-a-s-pa-betinget-kobstilbud/) - Bestyrelsen for Blue Vision A/S har i dag modtaget positivt svar fra Reponex Pharmaceuticals A/Shvor mere end 95% af aktionærerne per dags dato accepteret det afgivne betinget købstilbudfremsat den. 5. april 2022 som oplyst i meddelelse nr. 13.
- [Blue Vision A/S afgiver betinget købstilbud på Reponex Pharmaceuticals A/S](https://pharmaequitygroup.com/2022/04/06/blue-vision-a-s-afgiver-betinget-kobstilbud-pa-reponex-pharmaceuticals-a-s/) - Som senest oplyst i ved offentliggørelse af selskabets årsregnskab for 2021 i meddelse 11, offentliggør Blue Vision A/S i dag betinget købstilbud på Reponex Pharmaceuticals A/S CVR-nr. 30082346 og med hjemsted på adressen Slotsmarken 12, 1.th., 2970 Hørsholm, Danmark.
- [Årsrapport 2021 - Blue Vision](https://pharmaequitygroup.com/2022/04/01/arsrapport-2021-blue-vision/) - Bestyrelsen for Blue Vision A/S har dags dato (1. April 2022) behandlet og godkendt Selskabets årsrapport for 2021.
- [Reponex new CFO](https://pharmaequitygroup.com/2022/02/14/reponex-new-cfo/) - We are delighted to present the new CFO of Reponex Thomas Kaas Selsø who will join the company on the 1st of March 2022.
- [Ændring til finanskalender og oplysning om købstilbudsproces og prolongering af bankgæld, fra Blue Vision A/S](https://pharmaequitygroup.com/2022/02/09/aendring-til-finanskalender-og-oplysning-om-kobstilbudsproces-og-prolongering-af-bankgaeld-fra-blue-vision-a-s/) - Blue Vision A/S har i dag opdateret finanskalenderen, hvoraf det fremgår, at regnskabsaflæggelsen er udsattil den 23. marts 2022. Den ordinære generalforsamling er nu fastlagt til den 25. april 2022.
- [Blue Vision A/S – ændring til finanskalenderen og oplysning om købstilbudsproces](https://pharmaequitygroup.com/2022/01/19/blue-vision-a-s-aendring-til-finanskalenderen-og-oplysning-om-kobstilbudsproces/)
- [Reponex vurdering 2021-11-10](https://pharmaequitygroup.com/2021/11/11/reponex-vudering-2021-11-10/) - Blue Vision A/S – præcisering af vurdering af Reponex Pharmaceuticals A/S.
- [Reponex referat af generalforsamling 2021-11-10](https://pharmaequitygroup.com/2021/11/11/reponex-referat-af-generalforsamling-2021-11-11/) - Blue Vision A/S – referat af ekstraordinær generalforsamling
- [Reponex News 2021-10-19](https://pharmaequitygroup.com/2021/10/19/reponex-news-2021-10-19/) - Reponex Pharmaceuticals A/S has been selected as the target company for new activities. It is with great pleasure that Reponex today can announce that Blue Vision A/S has selected Reponex Pharmaceuticals A/S as the target company in connection with Blue Vision A/S’s strategic decision to seek new activities for the company.

## Pages

- [Home](https://pharmaequitygroup.com/) - Pharma Equity Group is a clinical phase two company listed on the Nasdaq Copenhagen stock exchange.
- [Board of Directors](https://pharmaequitygroup.com/board-of-directors/) - A strong and present leadership is the anchor of our business..
- [Company Articles](https://pharmaequitygroup.com/company-articles/) - Company Articles Selskabets Vedtægter 28.4.2026 Download Company Articles 28.4.2025 Download Selskabets Vedtægter 16.4.2026 Download Company Articles 16.4.2026 Download Selskabets Vedtægter 15.12.2025 Download Company Articles 15.12.2025 Download Selskabets vedtægter 11.10.2025 Download Company Articles 11.10.2025 Download Selskabets Vedtægter 16.04.2025 Download Company Articles 16.04.2025 Download Selskabets Vedtægter 01.04.2025 Download Company Articles 01.04.2025 Download Selskabets Vedtægter 04.10.2024 (Efter kapitalforhøjelse)
- [Management and Employees](https://pharmaequitygroup.com/management-and-employees/) - Our innovative mindset and human resources, is the key to our succes.. PEG & Reponex Management Team Our team is made up of visionary thinkers and experts, dedicated to positioning Pharma Equity Group and Reponex for long-term success Christian Tange Chief Executive Officer MORE Senior executive with 25 years ofexperience developing international growth companies in
- [Remuneration](https://pharmaequitygroup.com/remuneration-policy/) - Remuneration Policy 2025 Remuneration Report Download 2024 Remuneration Report Download 2023 Remuneration Report Download Remuneration Policy for Executive Management Pharma Equity Group A/SCVR no. 267914131. SCOPE AND PURPOSEThis Remuneration Policy (the “Policy”) applies to the Executive Management of Pharma Equity Group A/S, defined as the executives registered with the Danish Business Authority (e.g., the CEO).Exclusion
- [Investor Relations](https://pharmaequitygroup.com/investors/) - Annual General Meetings Please find below relevant investor relations documents. General meeting 2026 relevant documents English registration Form for the Annual General Meeting 16.04.2026 Download Danish registration Form for the Annual General Meeting 16.04.2026 Download English Postal Voting Form for the Annual General Meeting 16.04.2026 Download Danish Postal Voting Form for the Annual General Meeting
- [Financial Reports](https://pharmaequitygroup.com/financial-reports-2/) - Financial Reports of Pharma Equity Group A/S 2025 Annual Financial Report PDF Download ZIP Download Supplementary (Corrective information) to the interim report for H1 2025 PDF Download Supplementary information (Corrective information) to the annual report 2024 PDF Download 2025 H1 Consolidated Interim Financial Report PDF Download ZIP Download 2024 Annual Financial Report PDF Download ZIP
- [Data Ethics Policy](https://pharmaequitygroup.com/data-ethics-policy-2/) - Data Ethics Policy Statutory statement of data ethics pursuant to section 99 d of the Danish Financial Statements Act. This statement on data ethics is prepared pursuant to section 99 d of the Danish Financial Statements Act. Pharma Equity Group A/S (“Pharma Equity Group”) and its entities are committed to the protection of privacy and
- [Privacy Policy](https://pharmaequitygroup.com/privacy-policy/) - Privacy Policy and Notice At Pharma Equity Group, we place a very high priority on data security and confidentiality. This privacy policy and notice contains information about how we manage the information we obtain from our web page, information we process about our collaboration partners, potential collaboration partners, applicants and/or from other users of our
- [Diversity Policy](https://pharmaequitygroup.com/diversity-policy-2/) - Diversity Policy Pharma Equity Group is committed to continue working towards ensuring and furthering equal opportunities for all employees in respect of differences, such as gender, age, religion, sexual orientation and ethnicity, as all, in our view, serve as key components in ensuring a better, more dynamic and healthier business. We believe that employees should be recognized
- [Tax Policy](https://pharmaequitygroup.com/tax-policy/) - Tax Policy Purpose The Group wants to be recognized as a trusted partner acting in accordance with our values. We have a responsible and transparent approach to tax. As a part of this, we will avoid participation in aggressive tax planning that abuses the tax laws to obtain a tax benefit. We are committed to being responsible
- [Corporate Governance Statements](https://pharmaequitygroup.com/corporate-governance-statements/) - Corporate Governance Statements Corporate Governance Statements Documents Pharma Equity Group has, in accordance with the Danish Financial Statement Act, section 107b, prepared the following report (Danish: Lovpligtig redegørelse for virksomhedsledelse, jf. årsregnskabslovens § 107 b). The statement is part of the management report in the company’s annual (latest) report for the fiscal year 2025. 2025 -
- [Risk Management](https://pharmaequitygroup.com/risk-management/) - Risk Management Description of the main elements of Pharma Equity Group’s internal control and risk management systems in connection with the financial reporting process, according to section 107 b of the Danish Financial Statements Act. The statement is part of the management report in the company’s annual (latest) report for the fiscal year 2025. The Company’s
- [Code of Conduct](https://pharmaequitygroup.com/our-code-of-conduct-guidelines/) - Code of Conduct Our Code of Conduct is a set of guidelines, principles and rules outlining our expected behavior and ethical standards for our stakeholders in Pharma Equity group and its subsidiary Reponex A/S.Pharma Equity Group has, in accordance with the Danish Financial Statements Act, section 107b, prepared the following report on corporate governance. (Danish:
- [Financial Calendar](https://pharmaequitygroup.com/financial-calendar/) - Financial Calendar 2025 overview 2025 Key Dates – Last updated January 2025 Key dates Last updated February 3rd 2026 February 3rd 2025 Financial Calendar 2026 January 14th 2025 Financial Calendar 2025 March 13th 2023 Deadline for shareholder proposal - Annual General meeting March 31th 2023 Annual Report 2022 April 27, 2023 Annual General Meeting May
- [Committees](https://pharmaequitygroup.com/our-board-committees-are-smaller-groups-of-advisory-people-who-holds-the-purpose-of-advising-the-board-on-a-specific-area-of-operations/) - Committees To support the Board in its duties, the Board has established and appointed an Audit Committee, a Remuneration Committee, a Nomination Committee and a Business, Research and Development Committee. Our Board committees are smaller groups of advisory people who holds the purpose of advising the board on a specific area of operations and will be charged
- [Investors (new)](https://pharmaequitygroup.com/investors-new/) - We emphasize IR integrity and transparency. Together we transform the potential. Company Profile To Pharma Equity Group, openness and transparency are essential in maintaining good relations with investors. The company aims to give the market open, satisfactory information about the company’s operations, strategy and results with a view to ensuring fair pricing of the share
- [About](https://pharmaequitygroup.com/about-pharma-equity-group/) - We wish to make a difference for millions of people around the world About Pharma Equity Group Our vision Our vision is to be the biopharmaceutical group that develops the most effective local treatments for serious, acute and chronic inflammatory diseases. Our ambition is to reposition existing drugs to advance drug candidates to a clinical
- [Stock Information & Company Valuations](https://pharmaequitygroup.com/stock-information/) - Company valuations We invite you to examine Pharma Equity Group’s latest valuations. These analyses are an important part of our growth journey and give you insight into our financial health and future prospects. Understanding the value of your investments is critical in a dynamic market. By reading our valuations, you get a clear overview of
- [Subsidiary - Reponex Pharmaceuticals (new)](https://pharmaequitygroup.com/reponex-pharmaceuticals/) - Our subsidiaries is the key of our business.. Reponex Pharmaceuticals Driving Innovation Through Our Subsidiary Reponex Pharmaceuticals A/S is the subsidiary company of Pharma Equity Group. Reponex leverages repositioning to identify new therapeutic uses for active substances that are already utilized in existing treatments. This approach repurposes these substances for indications beyond their originally designated
- [News and Press](https://pharmaequitygroup.com/news-and-press/) - We want to be the industry's most communicative, both when it comes to the role and relevance of the industry and our own drug candidates for both patients and society as a whole. News & Press Hear what the media is saying about us and the drug candidates we are developing to exceed the current
- [Drug Candidates](https://pharmaequitygroup.com/drug-candidates/) - Repositioning known drugs into new intervention is the heart of what we do. Reponex drug candidate overview By repositioning our subsidiary Reponex finds new uses for active substances that are being used in other treatments. This means that the substances are used for other treatments than it was originally designated and registered for. The advantage
- [Colorectal Cancer & Colon Adenomas](https://pharmaequitygroup.com/colorectal-cancer-colon-adenomas/) - Colorectal Cancer & Colon Adenomas Recent findings reveal that the development, growth, and spread of colorectal cancer tumors are influenced by specific bacteria in the large bowel. Among these bacteria are toxin-producing fusobacteria that form biofilms and penetrate the bowel’s surface mucous layer. Some of these bacteria even infect bowel cancers, promoting tumor growth and
- [History](https://pharmaequitygroup.com/pharma-equity-group-is-a-patient-oriented-company/) - Our History Pharma Equity Group was established with a clear vision to invest in and develop innovative biopharmaceutical companies and assets. Founded by a team of seasoned professionals, the organization recognized the transformative potential of biopharmaceuticals in addressing unmet medical needs across various therapeutic areas. Over the years, Pharma Equity Group has built a reputation
- [Media resources](https://pharmaequitygroup.com/weve-created-a-media-resource-library/) - We engage with our stakeholders to ensure utmost knowledge sharing. Follow the journey. Media Resources We’ve created a Media Resource Library to giving you easy access to our brand assets, including our logo (in all its formats), and headshots of our top executives. Video resources Visit our Youtube channel Logo archive Download png Download png
- [Career](https://pharmaequitygroup.com/career/) - Join us Pharma Equity Group A/S consists of a dedicated team, s commited to support its subsidiary Reponex pharmaceuticals accomplish its clinical and financial objectives. If you have the mindset and a drive to be part of an entrepreneurial team, then please fill out the form below. First Name *Last Name *Email Address *Phone *Applied
- [Key Figures](https://pharmaequitygroup.com/key-figures/) - Key Figures Last Updated February 2023 Share Capital 1.022.963.883 DKK Share Size 1.00 DKK Noted Capital/Number of shares 1.022.963.883 Stock Exchange code/ISIN DK0061155009 Short Name PEG A
- [Prospectus and Documentation Reponex & Capital Increase](https://pharmaequitygroup.com/prospectus-and-documentation/) - Prospectus and Documentation Reponex & Capital Increase Disclaimer The information contained in this section of Pharma Equity Group A/S’ (the “Company”) web page that you are attempting to access is not intended for, and must not be accessed by, or distributed or disseminated, directly or indirectly, in whole or in part, to persons resident or
- [Governance](https://pharmaequitygroup.com/governance-2/) - Governance Company Articles Remuneration Risk Management Code of Conduct Tax Policy Data Ethics Policy Diversity Policy Corporate Governance Statements Privacy Policy Governance Company Articles Remuneration Risk Management Code of Conduct Tax Policy Data Ethics Policy Diversity Policy Corporate Governance Statements Privacy Policy Corporate Governance Policy Pharma Equity Group is subject to the recommendations prepared by
- [Crohns and Pouchitis](https://pharmaequitygroup.com/local-treatment-of-inflammatory-bowel-disease/) - Crohn’s disease and Pouchitis (IBD) The prevalence of Inflammatory Bowel Diseases (IBD) patients has witnessed a staggering rise in diagnoses over recent decades in Denmark with recent studies showing that numbers has reached 58.000. A development that has been in progress during the past decades. From 1995 to 2016, incidences of Crohn’s disease tripled, while
- [Peritonitis](https://pharmaequitygroup.com/peritonitis-inflammation/) - Bacterial Peritonitis The prevalence of Peritonitis The prevalence of peritonitis can vary depending on the underlying causes and populations studied. Reponex Pharmaceuticals’ peritonitis program delineates its therapeutic focus as follows: Primary Indication: Administration for bacterial peritonitis, targeting complex abdominal infections.Secondary Indications: Preventive measures against bacterial peritonitis. Utilizing insights from high-impact scientific literature [1,2,3,4,5]. Reponex Pharmaceuticals, subsidiary company
- [Chronic Skin Ulcers](https://pharmaequitygroup.com/cronic-skin-ulcers/) - Chronic Skin Ulcers & Infected Chronic Skin Ulcers Chronic ulcers in the form of venous leg ulcers and diabetic ulcers are a worldwide problem to the great inconvenience of the affected patients. There are several categories of non-healing wounds and ulcers, each of which has its own specialised treatment. These treatments include debridement of necrotic
- [Company Announcements](https://pharmaequitygroup.com/announcements/) - Company Announcements Communication and Marketing activities Newsletter 14.06.23 - Pharma Equity Group and Reponex Pharmaceuticals intensifies communication and marketing Download Press Releases Press Release 27.03.23 - Reponex is the first Danish biotech company to be listed on the Copenhagen stock exchange in 6 years Download Press Release 27.03.23 - Reponex Pharmaceuticals er det første danske
- [Newsletter](https://pharmaequitygroup.com/newsletter/) - Subscribe to our newsletter
- [Home Copy](https://pharmaequitygroup.com/elementor-2915-copy-2/) - What is repositioning?Christopher Burton, Chief Medical Officer, ReponexWatch videoNew investment approach in life scienceLearn more SUBSCRIBE TO PHARMA EQUITY GROUPS NEWSLETTER Stay up-to-date with Pharma Equity Group A/S news and developments. By subscribing, you’ll be among the first to hear about exciting new investment opportunities, the development of our portfolio company Reponex Pharmaceuticals and important
- [Home (old)](https://pharmaequitygroup.com/elementor-2915/) - Half-year results have been released Access the report here New investment approach in life science Learn more IPOLorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.Reponex Pharmaceuticals Corporate videoWatch videoNew investment approach in life scienceLearn more SUBSCRIBE TO PHARMA EQUITY GROUPS NEWSLETTER Stay up-to-date with Pharma
- [Contact](https://pharmaequitygroup.com/contact-new/) - Questions always have an answer.. Contact us +45 41 92 25 25 info@pharmaequitygroup.com Office hours: Monday to Thursday 8:00-17:00 Friday 8:00-16:00 Pharma Equity Group Slotsmarken 18, 2. th. DK-2970 Hørsholm Denmark General Enquiries Send us your enquiry and a member of our administrative support team will be in touch. Name Email Subject Message Send Know
- [Committees](https://pharmaequitygroup.com/our-board-committees-are-smaller-groups-of-advisory-people/)
- [Resource Library](https://pharmaequitygroup.com/resource-library/) - Staying close to, and having a large degree of transparency with our stakeholders is key to our success Resource Library We are incredibly focused on shareholder engagement, and therefore ensure that all published material is accessible. Please find below some of our ressources. Did you not meet what you were looking for please do not
- [Board of directors (old)](https://pharmaequitygroup.com/board-of-directors-old/) - About Us Board of Directors Christian Vinding ThomsenChairman of the Board Linkedin-in Has 20+ years of experience and is specialised within Regulatory Life Science, Healthcare, M&A and Corporate Law. Christian is also highly specialised in legal issues facing the pharmaceutical industry, and has represented multiple companies in issues such as GCP, GMP, GDP, Market Access
- [History (old)](https://pharmaequitygroup.com/history-old/) - About Us History The Heslet era From the beginning, Reponex Pharmaceuticals, the daughter company of Pharma Equity Group, has been a pronounced patient-oriented company, which seeks to improve the treatment not only of life-threatening diseases, but also of chronic conditions that greatly impair patients’ quality of life. This can be traced back to the company’s medical
- [About (old)](https://pharmaequitygroup.com/about-old-2/) - About Us Company Information Pharma Equity Group, listed on theNasdaq Copenhagen Stock Exchange, places a strong emphasis on its portfolio company, Reponex Pharmaceuticals A/S. As a clinical-stage biopharmaceutical company, Reponex Pharmaceuticals is dedicated to developing innovative and effective treatments for diseases that have a profound impact on patients and society, especially in cases where current
- [About - Company Information](https://pharmaequitygroup.com/about-company-information/) - About Us Company Information Pharma Equity Group, listed on the Nasdaq Copenhagen Stock Exchange, places a strong emphasis on its portfolio company, Reponex Pharmaceuticals A/S. As a clinical-stage biopharmaceutical company, Reponex Pharmaceuticals is dedicated to developing innovative and effective treatments for diseases that have a profound impact on patients and society, especially in cases where
- [Valuation](https://pharmaequitygroup.com/valuation/) - Valuation Investor Relations Financial Reports Financial Calendar Stock Information & Company Valuations Company Announcements Events & Presentations Video presentations Prospectus and Documentation Key Figures Shareholder Portal Subscribe to Newsletter Valuation Investor Relations Financial Reports Financial Calendar Stock Information & Company Valuations Company Announcements Events & Presentations Video presentations Prospectus and Documentation Key Figures Shareholder Portal
- [Contact](https://pharmaequitygroup.com/contact/) - Contact Pharma Equity Group Get in touch +45 41 92 25 25 info@pharmaequitygroup.com Office hours: Monday to Thursday 8:00-17:00 Friday 8:00-16:00 Pharma Equity Group Slotsmarken 18, 2. th. DK-2970 Hørsholm Denmark Connect with us Pharma Equity GroupSlotsmarken 18, 2.th.DK-2970 HørsholmDenmarkContact us at info@pharmaequitygroup.com Linkedin-in
- [News](https://pharmaequitygroup.com/news/) - Subscribe to News Investor Relations Financial Reports Financial Calendar Stock Information & Company Valuations Company Announcements Events & Presentations Video presentations Prospectus and Documentation Key Figures Shareholder Portal Subscribe to Newsletter Valuation Investor Relations Financial Reports Financial Calendar Stock Information & Company Valuations Company Announcements Events & Presentations Video presentations Prospectus and Documentation Key Figures
- [Video presentations](https://pharmaequitygroup.com/video-presentations/) - Video presentations Investor Relations Financial Reports Financial Calendar Stock Information & Company Valuations Company Announcements Events & Presentations Video presentations Prospectus and Documentation Key Figures Shareholder Portal Subscribe to Newsletter Valuation Investor Relations Financial Reports Financial Calendar Stock Information & Company Valuations Company Announcements Events & Presentations Video presentations Prospectus and Documentation Key Figures Shareholder
- [Events & Presentations](https://pharmaequitygroup.com/events-presentations/) - Events & Presentations Investor Relations Financial Reports Financial Calendar Stock Information & Company Valuations Company Announcements Events & Presentations Video presentations Prospectus and Documentation Key Figures Shareholder Portal Subscribe to Newsletter Valuation Investor Relations Financial Reports Financial Calendar Stock Information & Company Valuations Company Announcements Events & Presentations Video presentations Prospectus and Documentation Key Figures
- [New drug delivery platform (new)](https://pharmaequitygroup.com/drug-delivery-platform/) - We wish to make a difference for millions of people around the world New drug delivery platform
- [Patients (new)](https://pharmaequitygroup.com/patients-new/) - Life as Crohn's Colitis patient Life as a Crohn’s Colitis patient… Patient stories Together with the leading patient associations we build authentic depictions of the everyday life and the challenges that a life with a threatening disease hold. We do this with the aim of increasing awareness and knowledgeIn below documentaries you will get a
- [Colon Adenomas (new)](https://pharmaequitygroup.com/colon-adenomas/) - Colon Adenomas Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
- [Colitis and Crohns patients (new)](https://pharmaequitygroup.com/colitis-crohns-patients-new/) - Colitis and Crohn's patients NY TEKSTER OG FILM
- [Colorectal Cancer patients (new)](https://pharmaequitygroup.com/colorectal-cancer-patients-new/) - Colorectal Cancer patients NY TEKSTER
- [Home Copy (new slider)](https://pharmaequitygroup.com/elementor-2915-copy-3/) - New investment approach in life science Learn more SUBSCRIBE TO PHARMA EQUITY GROUPS NEWSLETTER Stay up-to-date with Pharma Equity Group A/S news and developments. By subscribing, you’ll be among the first to hear about exciting new investment opportunities, the development of our portfolio company Reponex Pharmaceuticals and important company announcements. To sign up, simply press
- [News(old)](https://pharmaequitygroup.com/news-old/)
- [Tax Policy (old)](https://pharmaequitygroup.com/tax-policy-old/)
- [Subscribe to News(old)](https://pharmaequitygroup.com/subscribe-to-news-old/)
- [Stock Information(old)](https://pharmaequitygroup.com/stock-information-old/)
- [Risk Management(old)](https://pharmaequitygroup.com/risk-management-old/)
- [Remuneration Policy(old)](https://pharmaequitygroup.com/remuneration-policy-old/)
- [Prospectus and Documentation Reponex & Capital Increase(old)](https://pharmaequitygroup.com/reponex/)
- [Privacy Policy-old](https://pharmaequitygroup.com/privacy-policy-old/) - Who we are Our website address is: http://v2.pharmaequitygroup.com. What personal data we collect and why we collect it Comments When visitors leave comments on the site we collect the data shown in the comments form, and also the visitor’s IP address and browser user agent string to help spam detection. An anonymized string created from
- [Key Figures(old)](https://pharmaequitygroup.com/key-figures-old/)
- [Investors(old)](https://pharmaequitygroup.com/investors-old/)
- [Homepage(old)](https://pharmaequitygroup.com/homepage-old/)
- [Governance(old)](https://pharmaequitygroup.com/governance-old/)
- [Financial Calender(old)](https://pharmaequitygroup.com/financial-calender-old/)
- [Events & Presentations(old)](https://pharmaequitygroup.com/events-old/)
- [Data Ethics Policy(old)](https://pharmaequitygroup.com/data-ethics-policy-old/)
- [Contact (old)](https://pharmaequitygroup.com/contact-old/)
- [Diversity Policy (old)](https://pharmaequitygroup.com/diversity-policy-old/)
- [Corporate Governance Statements (old)](https://pharmaequitygroup.com/corporate-governance-statements-old/)
- [Company Articles(old)](https://pharmaequitygroup.com/company-articles-old/)
- [Code of Conduct(old)](https://pharmaequitygroup.com/code-of-conduct-old/)
- [Announcements (old)](https://pharmaequitygroup.com/announcements-old/) - REPONEX NEWS.
- [About (old)](https://pharmaequitygroup.com/about-old/)
- [Privacy Policy](https://pharmaequitygroup.com/legal/)
- [Financial Reports](https://pharmaequitygroup.com/financial-reports/)
- [General Meetings](https://pharmaequitygroup.com/general-meetings/)
- [Sustainability Policy](https://pharmaequitygroup.com/sustainability-policy/)
- [Quality Policy](https://pharmaequitygroup.com/quality-policy/)
- [FAQ](https://pharmaequitygroup.com/faq/)
- [Careers](https://pharmaequitygroup.com/careers/)
- [Posts](https://pharmaequitygroup.com/posts/)

## Elementor Header & Footer Builder

- [](https://pharmaequitygroup.com/elementor-hf/2901/)

## Categories

- [Uncategorized](https://pharmaequitygroup.com/category/uncategorized/)
- [Post](https://pharmaequitygroup.com/category/post/)
- [Reponex News](https://pharmaequitygroup.com/category/reponex-news/)
- [Media](https://pharmaequitygroup.com/category/media/)